DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Goldman Sachs - 2 — CNBC's Michael Bloom - 2 TD Cowen - 1 Freyr - 1 FREY - 1 Goldman - 1 it's - 1 We're - 1
Top related locs:
EVgo Cybersecurity Corning Albemarle LTHM 2024E Kura
Top related orgs:
Syndax Pharmaceuticals - 2 EV - 1 Apple - 1 BMO - 1 Bank of America - 1 Microsoft - 1 GPS - 1 Alto Networks - 1

Search resuls for: "Syndax Pharma"


4 mentions found


☆ Here are Wednesday's biggest analyst calls: Nvidia, Apple, Microsoft, Gap, Verizon, Alphabet & more
  + stars: | 2023-10-25 | by ( Michael Bloom | ) www.cnbc.com   time to read: +9 min
Wells Fargo upgrades Gap to overweight from equal weight Wells said the turnaround is taking shape for Gap. Deutsche Bank upgrades Livent to buy from hold Deutsche said it sees an attractive entry point for the lithium company. Bank of America downgrades TransUnion to underperform from buy Bank of America double downgraded the stock due to concerns about consumer lending. Bank of America initiates Syndax as buy Bank of America said it sees upside for the pharmaceutical company. Monness, Crespi, Hardt & Co. downgrades Alphabet to neutral from buy Monness said it's concerned about regulatory headwinds.
Persons: TD Cowen, Freyr, FREY, Goldman Sachs, Goldman, it's, We're, Wells, Needham, Etsy, Piper Sandler, Piper, TRU, SocGen, Bernstein, Deutsche Bank downgrades Corning, 2H24, Jefferies, Monness, Crespi, Hardt, Piper Sandler downgrades Livent Organizations: EV, Apple, BMO, Bank of America, Microsoft, GPS, Alto Networks, Deutsche Bank, Deutsche, Citi, TAM, Barclays, Verizon, Piper Sandler downgrades Regions, Citizens Financial, RF, " Bank of America, Farfetch, Machinery, UBS, Nvidia, Veeva, Commercial, Syndax Pharmaceuticals Locations: EVgo, Cybersecurity, Corning, Albemarle, LTHM
☆ Here’s why this under-the-radar biopharma stock could leap nearly 140%, Goldman Sachs says
  + stars: | 2023-10-11 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +2 min
An overly negative reception to clinical results could mean investors are missing out on potential upside for Syndax Pharmaceuticals , according to Goldman Sachs. The investment bank initiated coverage of the biopharmaceutical company on Wednesday with a buy rating, setting a 12-month price target of $30. This implies potential upside of 137% from the stock's Tuesday closing price of $12.65. In its Oct. 2 announcement, Syndax said it had "positive topline data" from the protocol-defined pooled analysis of this trial. "Based on our analysis and view, we believe the stock is currently trading below the value of near-term commercial opportunities ex-cash/-terminal value," he wrote.
Persons: Goldman Sachs, Syndax, Chris Shibutani, Shibutani, — CNBC's Michael Bloom Organizations: Syndax Pharmaceuticals Locations: 2024E
☆ Bank of America says this under-the-radar oncology stock can rally 180%
  + stars: | 2023-08-11 | by ( Pia Singh | ) www.cnbc.com   time to read: +2 min
Bank of America thinks Kura Oncology could be a winner in blood cancer treatment, believing the stock could nearly triple in value. The bank initiated research coverage of the clinical-stage biotech company with a buy rating and $31 per share price target. "Early clinical data has been favorable, where treatment with ziftomenib monotherapy produced robust responses in a heavily pretreated patient population where outcomes are often poor." Kura Oncology's stock price briefly rose as much as 6.5% in early Friday trading. KURA 1Y mountain Kura Oncology stock.
Persons: Jason Zemansky, ziftomenib monotherapy, Zemansky, Cash, BofA, — CNBC's Michael Bloom Organizations: of America, Bank of America's, Syndax Pharma, FactSet Locations: Kura
☆ This little-known pharma stock can rally more than 60% in 2023, JPMorgan says
  + stars: | 2023-01-03 | by ( Sarah Min | ) www.cnbc.com   time to read: +2 min
A promising treatment for acute leukemia makes Syndax Pharmaceuticals an attractive stock, JPMorgan said. Analyst Anupam Rama initiated coverage of Syndax with an overweight rating ahead of what could be significant new data on the company's cancer therapy called revumenib. Shares of Syndax outperformed last year, rising more than 16%. The analyst's price target of $41 means the biotech stock could see another 61% increase from Friday's closing price. Additionally, the analyst is anticipating further data on another treatment for chronic graft-versus-host disease (cGVHD) called axatilimab in mid-2023.
0 next >>
Total: 4